Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Edward Rubin, MD board-certified in Pain Medicine and Anesthesiology, with fellowship training at Cornell, Columbia, Hospital for Special Surgery, and Memorial Sloan Kettering
A third-party browser plugin, such as Ghostery or NoScript, is preventing JavaScript from running
Importantly, AOD-9604 does not bind to growth hormone receptors or stimulate IGF-1 production, which distinguishes it from full-length human growth hormone
The difference was meaningful in research terms but small in absolute terms, which is why responsible framing presents AOD 9604 as a possible adjunct to diet and training, not a replacement for them
AOD-9604's niche is as an adjunct for individuals seeking modest additional fat mobilization with minimal side effects, not as a primary obesity treatment
